Sort   by:  
 Page size 
MetabolomicsCDK4/6 inhibitor-mediated cell overgrowth triggers an osmotic stress response and chronic p38MAPK activation to promote long-term cell cycle arrest

Cell size and the cell cycle are intrinsically coupled and abnormal increases in cell size are associated with senescence and permanent cell cycle arrest. The mechanism by which overgrowth primes cells to withdraw from the cell cycle remains unknown. We investigate this here using CDK4/6 inhibito...

2025-10-24 | MTBLS5868 | MetaboLights
MetabolomicsRBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death

Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) pati...

2025-04-15 | MTBLS10792 | MetaboLights
MetabolomicsCell overgrowth potentiates osmotic and replication stresses to promote p38/p53/p21-dependent senescence
Abnormal increases in cell size are associated with senescence and cell cycle exit. The mechanisms by which overgrowth primes cells to withdraw from the cell cycle remain unknown. We address this question using CDK4/6 inhibitors, which arrest cells in G0/G1 and are licensed to treat advanced HR+/HER...
2025-10-24 | MTBLS8698 | MetaboLights
ProteomicsCDK4/6 inhibitor resistance in prostate cancer
CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre...
ORGANISM(S): Homo sapiens (Human) 
2018-05-16 | PXD006561 | Pride
Palbociclib Lapc4 Ribociclib Cdk4/6 Prostate cancer Lncap 
ProteomicsInhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer.
CDK4/6 inhibition is the standard of care for estrogen receptor positive (ER+) breast cancer, although cytostasis is frequently observed, and new treatment strategies that enhance efficacy are required. We performed a genome-wide CRISPR screen to identify genetic determinants of CDK4/6 inhibitors se...
ORGANISM(S): Homo sapiens (Human) 
2023-06-20 | PXD043133 | Pride
Breast cancer Gpx4 Cdk4/6 inhibitor 
TranscriptomicsExpression data from vehicle or PD-0332991 treated human T-ALL lines
Cyclin D3 is critical hematopoiesis and loss of cyclin D3 leads to resistance to transformation of bone marrow progenitors by Notch1-IC. We used a small molecule targeting cyclin D3:CDK4/6 activity to study whether its inhibition is an effective therapeutic strategy. We analyzed T-ALL lines in vitro...
ORGANISM(S): Homo sapiens 
2012-12-13 | E-GEOD-40635 | biostudies-arrayexpress
GenomicsAcquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma
Acquired resistance to MEK-CDK4/6 inhibitor combinations in cutaneous melanoma
PRJNA435576 | ENA
TranscriptomicsA Systematic Substrate Screen Links Cyclin D-Dependent Kinases to Senescence Suppression in Cancer Cells through FOXM1
Gene expression (mRNA profiling) of U2OS osteosarcoma cells treated with 1 mM of the CDK4/6-specific inhibitor, PD0332991, versus vehicle (DMSO) for 4 hours Here, we monitored the early transcriptional response to acute inhibition of CDK4/6 catalytic activity. As PD0332991 substantially induced sene...
ORGANISM(S): Homo sapiens 
2011-11-18 | E-GEOD-32182 | biostudies-arrayexpress
TranscriptomicsExpression profile of BCR-ABL1-transformed, Cdk4 R24C, Cdk6 R31C cell lines
Cdk4 and Cdk6 are two related kinases that bind D-type cyclins and regulate cell cycle progression. Due to their relevance in cancer, Cdk4/6 inhibitors are currently in advanced clinical trials in multiple tumor types. Cdk4/6 are inhibited by INK4 proteins that exert tumor suppressing functions. To ...
ORGANISM(S): Mus musculus 
2014-11-04 | E-GEOD-59024 | biostudies-arrayexpress
GenomicsInhibition of CK1e potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
Inhibition of CK1e potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
PRJNA736983 | ENA
Sort   by:  
 Page size